Home › Mitral Valve Insufficiency › NCT03242642
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
Recruiting
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO Trial
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Moderate to severe or severe symptomatic mitral regurgitation * Local site multidisciplinary heart team experienced in mitral valve therapies agrees that the subject is unsuitable for treatment with approved transcatheter repair or conventional mitral valve intervention Exclusion Criteria: * prior transcatheter mitral valve procedure with device currently implanted * anatomic contraindications * prohibitive mitral annular calcification * left ventricular ejection fraction \<25% * need for emergent or urgent surgery * hemodynamic instability
About the study
Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device.
What is being tested
- Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) (device)
- Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) (device)
Sponsor: Medtronic Cardiovascular · Participants: 1,056 · Started: Oct 23, 2017
Contact the study team
- Megan Wilder Fredrickson · Phone: 612-469-1749
Official record on ClinicalTrials.gov — NCT03242642
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.